Free Trial
→ I was right about SpaceX (From Brownstone Research) (Ad)tc pixel Free SABSW Stock Alerts

SAB Biotherapeutics (SABSW) Competitors

$0.02 -0.01 (-28.07%)
Closing price 05/14/2026 03:58 PM Eastern
Extended Trading
$0.02 0.00 (0.00%)
As of 05/14/2026 04:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

SABSW vs. AIMDW, ALVOW, ACABW, RNA, and BFRIW

Should you buy SAB Biotherapeutics stock or one of its competitors? MarketBeat compares SAB Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SAB Biotherapeutics include Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), Avidity Biosciences (RNA), and Biofrontera (BFRIW). These companies are all part of the "pharmaceutical products" industry.

How does SAB Biotherapeutics compare to Ainos?

SAB Biotherapeutics (NASDAQ:SABSW) and Ainos (NASDAQ:AIMDW) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

In the previous week, SAB Biotherapeutics had 1 more articles in the media than Ainos. MarketBeat recorded 2 mentions for SAB Biotherapeutics and 1 mentions for Ainos. Ainos' average media sentiment score of 1.89 beat SAB Biotherapeutics' score of 1.44 indicating that Ainos is being referred to more favorably in the news media.

Company Overall Sentiment
SAB Biotherapeutics Positive
Ainos Very Positive

Company Net Margins Return on Equity Return on Assets
SAB BiotherapeuticsN/A N/A N/A
Ainos N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SAB BiotherapeuticsN/AN/AN/AN/AN/A
Ainos$124.16KN/AN/AN/AN/A

Summary

Ainos beats SAB Biotherapeutics on 2 of the 3 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Alvotech?

SAB Biotherapeutics (NASDAQ:SABSW) and Alvotech (NASDAQ:ALVOW) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

In the previous week, SAB Biotherapeutics and SAB Biotherapeutics both had 2 articles in the media. SAB Biotherapeutics' average media sentiment score of 1.44 equaled Alvotech'saverage media sentiment score.

Company Overall Sentiment
SAB Biotherapeutics Positive
Alvotech Positive

Company Net Margins Return on Equity Return on Assets
SAB BiotherapeuticsN/A N/A N/A
Alvotech N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SAB BiotherapeuticsN/AN/AN/AN/AN/A
Alvotech$586.32MN/AN/AN/AN/A

Summary

Alvotech beats SAB Biotherapeutics on 1 of the 1 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Atlantic Coastal Acquisition Corp. II?

Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) and SAB Biotherapeutics (NASDAQ:SABSW) are both pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/A
SAB BiotherapeuticsN/AN/AN/AN/AN/A

In the previous week, SAB Biotherapeutics had 2 more articles in the media than Atlantic Coastal Acquisition Corp. II. MarketBeat recorded 2 mentions for SAB Biotherapeutics and 0 mentions for Atlantic Coastal Acquisition Corp. II. SAB Biotherapeutics' average media sentiment score of 1.44 beat Atlantic Coastal Acquisition Corp. II's score of 0.00 indicating that SAB Biotherapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Atlantic Coastal Acquisition Corp. II Neutral
SAB Biotherapeutics Positive

Company Net Margins Return on Equity Return on Assets
Atlantic Coastal Acquisition Corp. IIN/A N/A N/A
SAB Biotherapeutics N/A N/A N/A

Summary

SAB Biotherapeutics beats Atlantic Coastal Acquisition Corp. II on 2 of the 2 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Avidity Biosciences?

Avidity Biosciences (NASDAQ:RNA) and SAB Biotherapeutics (NASDAQ:SABSW) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability.

Avidity Biosciences currently has a consensus target price of $69.42, indicating a potential upside of 423.14%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Avidity Biosciences is more favorable than SAB Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avidity Biosciences
1 Sell rating(s)
12 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.32
SAB Biotherapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

SAB Biotherapeutics has lower revenue, but higher earnings than Avidity Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avidity Biosciences$18.62MN/A-$322.30MN/AN/A
SAB BiotherapeuticsN/AN/AN/AN/AN/A

In the previous week, Avidity Biosciences had 1 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 3 mentions for Avidity Biosciences and 2 mentions for SAB Biotherapeutics. Avidity Biosciences' average media sentiment score of 1.63 beat SAB Biotherapeutics' score of 1.44 indicating that Avidity Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Avidity Biosciences Very Positive
SAB Biotherapeutics Positive

SAB Biotherapeutics has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. SAB Biotherapeutics' return on equity of 0.00% beat Avidity Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Avidity Biosciences-3,650.39% -44.92% -39.57%
SAB Biotherapeutics N/A N/A N/A

Summary

Avidity Biosciences beats SAB Biotherapeutics on 7 of the 10 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Biofrontera?

Biofrontera (NASDAQ:BFRIW) and SAB Biotherapeutics (NASDAQ:SABSW) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$41.71MN/AN/AN/AN/A
SAB BiotherapeuticsN/AN/AN/AN/AN/A

In the previous week, SAB Biotherapeutics had 1 more articles in the media than Biofrontera. MarketBeat recorded 2 mentions for SAB Biotherapeutics and 1 mentions for Biofrontera. Biofrontera's average media sentiment score of 1.87 beat SAB Biotherapeutics' score of 1.44 indicating that Biofrontera is being referred to more favorably in the media.

Company Overall Sentiment
Biofrontera Very Positive
SAB Biotherapeutics Positive

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
SAB Biotherapeutics N/A N/A N/A

Summary

Biofrontera beats SAB Biotherapeutics on 2 of the 3 factors compared between the two stocks.

Get SAB Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SABSW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SABSW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SABSW vs. The Competition

Export
MetricSAB BiotherapeuticsBiotechnology IndustryMedical SectorNASDAQ Exchange
Market CapN/A$460.03M$6.34B$12.37B
Dividend YieldN/A3.86%2.80%5.35%
P/E RatioN/A3.8320.6625.63
Price / SalesN/A7,642.59542.6376.59
Price / CashN/A13.1343.2656.33
Price / BookN/A83.929.936.97
Net IncomeN/A-$96.07M$3.55B$333.62M
7 Day PerformanceN/A1.25%1.70%1.09%
1 Month PerformanceN/A0.53%0.49%3.08%
1 Year PerformanceN/A69.22%39.41%35.68%

SAB Biotherapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SABSW
SAB Biotherapeutics
N/A$0.02
-28.1%		N/A-26.1%$0.00N/AN/A140
AIMDW
Ainos
N/A$0.09
-17.7%		N/A-1.4%$0.00$124.16KN/A40
ALVOW
Alvotech
N/A$0.28
+29.4%		N/A-85.9%$0.00$586.32MN/A4
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.00
flat		N/AN/A$0.00N/AN/A15
RNA
Avidity Biosciences
2.1014 of 5 stars		$12.91
+0.3%		$69.42
+437.7%		-53.3%$0.00$18.62MN/A190

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SABSW) was last updated on 5/15/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel